←back to Blog

Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease

J Hematol Oncol. 2026 Nov 18;19(1):106. doi: 10.1186/s13045-026-01870-y.

ABSTRACT

BACKGROUND: Extramedullary disease (EMD) predicts poor outcomes after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM). KQ-2003 is a bicistronic BCMA/CD19 CAR T-cell product incorporating 4-1BB and CD28-YMFM costimulatory domains. We assessed its activity and intralesional biology, focusing on EMD.

METHODS: Twenty-four patients received KQ-2003 (21 trial participants; three compassionate-use patients). Hematologic and EMD responses were assessed using International Myeloma Working Group (IMWG) and Italian Myeloma criteria for PET Use, respectively. Bone marrow minimal residual disease (MRD) was assessed by next-generation flow cytometry (10— 5 sensitivity). Progression-free survival (PFS) was analyzed using Kaplan-Meier and Cox methods. Longitudinal single-cell RNA sequencing profiled one patient’s infusion product, serial blood, and spatially distinct EMD biopsies.

RESULTS: Patients had received a median of five prior lines; 18 (75.0%) were triple-class refractory, six (25.0%) penta-refractory, 23 (95.8%) had high-risk cytogenetics, and 15 (62.5%) had EMD. All 20 patients with measurable hematologic disease achieved hematologic responses (18 [90.0%] complete/stringent complete); IMWG-defined overall response rate was 95.0%. Fourteen (93.3%) of 15 EMD patients achieved metabolic responses (13 [86.7%] complete). Among 19 baseline MRD-positive patients, 12 (63.2%) became MRD-negative by month 6; 10 and six also had documented negativity at months 12 and 24, respectively. At 29.2 months’ median follow-up, median PFS was 24.0 months (95% CI, 15.0-not reached); no significant difference was detected by baseline EMD status (HR, 0.92; P = 0.89). Among the 21 trial participants, grade ≥ 3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in one (4.8%) and two (9.5%), respectively; two treatment-related fatal pneumonias occurred. Single-patient longitudinal profiling revealed proliferating lesion-infiltrating CAR T cells with increased CCL3/CCL4 expression and tumor-cell apoptotic and necroptotic transcriptional programs. Trajectory analysis suggested transcriptional links between tissue effectors and circulating CCL5-positive memory-like CAR T cells. CellChat predicted BCMA-related tumor-microenvironment interactions and immune-cell interactions involving circulating CAR T cells.

CONCLUSIONS: KQ-2003 produced deep, durable hematologic and metabolic responses in heavily pretreated, high-risk RRMM, including EMD. Intralesional profiling identified CAR T-cell proliferation, tumor-cell death-associated programs, and candidate microenvironmental interactions. These findings warrant further evaluation of this dual-targeting strategy in EMD.

TRIAL REGISTRATION: ClinicalTrials.gov, NCT04714827; registered 19 January 2021.

PMID:43053183 | DOI:10.1186/s13045-026-01870-y